Day: October 12, 2026

BMS Reports 42-Month Progression-Free Survival with ZENBEXUS Combination in Multiple Myeloma Trial Pharm up 361

Pharm up 361

BMS Reports 42-Month Progression-Free Survival with ZENBEXUS Combination in Multiple Myeloma Trial

Pharm'Up

Bristol Myers Squibb (BMS) has announced positive results from its Phase III EXCALIBER-RRMM study evaluating ZENBEXUS (iberdomide)...

Pfizer TUKYSA Receives FDA Approval for HER2+ Breast Cancer Maintenance Treatment Pharm up 360

Pharm up 360

Pfizer TUKYSA Receives FDA Approval for HER2+ Breast Cancer Maintenance Treatment

Pharm'Up

The U.S. Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab...